Jacob S. Elkins

Neurology

400 Parnassus Ave
San Francisco, CA 94143

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 29 publications

Quantitative Muscle Magnetic Resonance Outcomes in Patients With Duchenne Muscular Dystrophy: An Exploratory Analysis From the EMBARK Randomized Clinical Trial.

Quantitative Muscle Magnetic Resonance Outcomes in Patients With Duchenne Muscular Dystrophy: An Exploratory Analysis From the EMBARK Randomized Clinical Trial.

Journal: JAMA neurology

Published: May 12, 2025

Caregiver Global Impression Observations from EMBARK: A Phase 3 Study Evaluating Delandistrogene Moxeparvovec in Ambulatory Patients with Duchenne Muscular Dystrophy.

Caregiver Global Impression Observations from EMBARK: A Phase 3 Study Evaluating Delandistrogene Moxeparvovec in Ambulatory Patients with Duchenne Muscular Dystrophy.

Journal: Neurology and therapy

Published: August 23, 2024

AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial.

AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial.

Journal: Nature medicine

Published: March 22, 2024

Post-stroke blood-brain barrier disruption predicts poor outcome in patients enrolled in the ACTION study.

Post-stroke blood-brain barrier disruption predicts poor outcome in patients enrolled in the ACTION study.

Journal: Journal of neuroimaging : official journal of the American Society of Neuroimaging

Published: January 29, 2021

Safety and Efficacy of Natalizumab as Adjunctive Therapy for People With Drug-Resistant Epilepsy: A Phase 2 Study.

Safety and Efficacy of Natalizumab as Adjunctive Therapy for People With Drug-Resistant Epilepsy: A Phase 2 Study.

Journal: Neurology

Published: January 21, 2021

Impact of informative censoring on the treatment effect estimate of disability worsening in multiple sclerosis clinical trials.

Impact of informative censoring on the treatment effect estimate of disability worsening in multiple sclerosis clinical trials.

Journal: Multiple sclerosis and related disorders

Published: July 22, 2019

Natalizumab in acute ischemic stroke (ACTION II): A randomized, placebo-controlled trial.

Natalizumab in acute ischemic stroke (ACTION II): A randomized, placebo-controlled trial.

Journal: Neurology

Published: May 24, 2019

Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine.

Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine.

Journal: CNS drugs

Published: December 12, 2018

Immune Response to Seasonal Influenza Vaccine in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Long-term Daclizumab Beta: A Prospective, Open-Label, Single-Arm Study.

Immune Response to Seasonal Influenza Vaccine in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Long-term Daclizumab Beta: A Prospective, Open-Label, Single-Arm Study.

Journal: International journal of MS care

Published: June 13, 2017

Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study.

Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: May 10, 2017

Exposure-disease response analysis of natalizumab in subjects with multiple sclerosis.

Exposure-disease response analysis of natalizumab in subjects with multiple sclerosis.

Journal: Journal of pharmacokinetics and pharmacodynamics

Published: November 10, 2016

Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial.

Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial.

Journal: The Lancet. Neurology

Published: June 03, 2016

Showing 1-12 of 29

Last Updated: 09/26/2026